We are live on ! Find out more
BDRX

Biodexa Pharmaceuticals
BDRX

4 hedge funds and large institutions have $55.8K invested in Biodexa Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

228% more capital invested

Capital invested by funds: $17K → $55.8K (+$38.8K)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.25% more ownership

Funds ownership: 0.02% → 0.27% (+0.25%)

0% more funds holding

Funds holding: 4 → 4 (0)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$48.3K
2
GI
GAMMA Investing
California
+$1.11K

Top Sellers

Rank Fund Capital Flow
1
SS
SBI Securities
Japan
-$3.23K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$46.1K +$48.3K +1,345 +3,363%
GI
2
GAMMA Investing
California
$8.99K +$1.11K +31 +13%
SS
3
SBI Securities
Japan
$765 -$3.23K -90 -80%
RhumbLine Advisers
4
RhumbLine Advisers
Massachusetts
$32 – – –

BDRX Hedge Fund Activity: Q3 2025 in Review

4 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q3 2025, worth a combined $55.8K — up 228% from $17K a quarter earlier.

Fund positioning in BDRX was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, adding an estimated $48.3K. The largest seller was SBI Securities, cutting an estimated $3.23K.

  • 4 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $55.8K of Biodexa Pharmaceuticals stock for Q3 2025, up 228% quarter-over-quarter.
  • 0 funds opened new Biodexa Pharmaceuticals positions in Q3 2025 and 0 closed out.
  • The largest Biodexa Pharmaceuticals buyer in Q3 2025 was UBS Group, an estimated $48.3K added.
  • The largest Biodexa Pharmaceuticals seller in Q3 2025 was SBI Securities, an estimated $3.23K sold.

Based on aggregated 13F filings for Q3 2025.